CRISPR Therapeutics AG
CRSPUS売上高
$4M
百万USD
営業利益
$-665M
百万USD
純利益
$-582M
百万USD
ROE
-30.3%
最新FY
EPS
$-6.47
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $1M | $-113M | $-1.51 |
| FY2021 | Q2 | $901M | $759M | $9.44 |
| FY2021 | Q3 | $1M | $-127M | $-1.67 |
| FY2021 | FY | $915M | $378M | $4.70 |
| FY2022 | Q1 | $1M | $-179M | $-2.32 |
| FY2022 | Q2 | $0M | $-186M | $-2.40 |
| FY2022 | Q3 | $0M | $-175M | $-2.24 |
| FY2022 | FY | $1M | $-650M | $-8.36 |
| FY2023 | Q1 | $100M | $-53M | $-0.67 |
| FY2023 | Q2 | $70M | $-78M | $-0.98 |
| FY2023 | Q3 | $0M | $-112M | $-1.41 |
| FY2023 | FY | $371M | $-154M | $-1.94 |
| FY2024 | Q1 | $1M | $-117M | $-1.43 |
| FY2024 | Q2 | $1M | $-126M | $-1.49 |
| FY2024 | Q3 | $1M | $-86M | $-1.01 |
| FY2024 | FY | $37M | $-366M | $-4.34 |
| FY2025 | Q1 | $1M | $-136M | $-1.58 |
| FY2025 | Q2 | $1M | $-209M | $-2.40 |
| FY2025 | Q3 | $1M | $-106M | $-1.17 |
| FY2025 | FY | $4M | $-582M | $-6.47 |
| FY2026 | Q1 | $1M | $-123M | $-1.28 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | - | $1M | $915M | $1M | $371M | $37M | $4M |
| 営業利益 | $-68M | $-65M | $-159M | $47M | $-354M | $374M | $-673M | $-223M | $-467M | $-665M |
| 純利益 | $-23M | $-68M | $-165M | $67M | $-349M | $378M | $-650M | $-154M | $-366M | $-582M |
| 総資産 | $345M | $271M | $489M | $1.1B | $1.8B | $2.8B | $2.2B | $2.2B | $2.2B | $2.3B |
| 純資産 | $233M | $188M | $392M | - | - | - | - | - | - | - |
| 自己資本 | $233M | $188M | $392M | $939M | $1.7B | $2.4B | $1.9B | $1.9B | $1.9B | $1.9B |
| 営業CF | - | - | $-96M | $57M | $-238M | $539M | $-496M | $-260M | $-143M | $-345M |
| EPS | - | - | - | $1.17 | $-5.29 | $4.70 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| BPS | $5.85 | $4.00 | $7.50 | $15.44 | $22.06 | $31.13 | $23.85 | $23.45 | $22.53 | $20.02 |
| ROE | -10.0% | -36.4% | -42.1% | 7.1% | -21.0% | 15.7% | -34.7% | -8.2% | -19.0% | -30.3% |